Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (762)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (413)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2092)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (89)
  5. Editorial (80)
  6. Guidelines (36)
  7. Correspondence (24)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (762)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (80)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1668)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4627)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Oh, D. Y.; Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, S. L.; Sangro, B.; Kelley, R. K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Meeting Abstract

    Oh, D. Y.; Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
    Meeting Abstract

    Chen, T. W. W.; Sanfilippo, R.; Jones, R. L.; Schuetze, S. M.; Sebio Garcia, A.; Alvarez, R. M.; Bui, N.; Ahn, J. H.; Loong, H. H. F.; Yen, C. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Meeting Abstract

    Yoshino, T.; André, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Lifetime ovulatory years and risk of epithelial ovarian cancer: A multinational pooled analysis
    Journal Article

    Fu, Z.; Brooks, M. M.; Irvin, S.; Jordan, S.; Aben, K. K. H.; Anton-Culver, H.; Bandera, E.; Beckmann, M. W.; Berchuck, A.; Brooks-Wilson, A.; more...
    JNCI: Journal of the National Cancer Institute (2023)

    Fulltext@MSK | Save
  • Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
    Journal Article

    Watts, E. L.; Perez-Cornago, A.; Fensom, G. K.; Smith-Byrne, K.; Noor, U.; Andrews, C. D.; Gunter, M. J.; Holmes, M.; Martin, R. M.; Tsilidis, K. K.; more...
    International Journal of Epidemiology (2023)

    Fulltext@MSK | Save
  • Differential mosquito attraction to humans is associated with skin-derived carboxylic acid levels
    Meeting Abstract

    De Obaldia, M. E.; Morita, T.; Dedmon, L. C.; Boehmler, D. J.; Jiang, C. S.; Zeledon, E. V.; Cross, J. R.; Vosshall, L. B.
    Chemical Senses (2023)

    Fulltext@MSK | Save